MKM. R. Kamaliyeva

M. R. Kamaliyeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


M. R. Kamaliyeva has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Joint Role of Serum Markers of Congestion or Myocardial Necrosis And Speckle Tracking Echocardiography in The Detection of Early Subtle Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer

    by N. Raiimbek Uulu, I. V. Pershukov, L. V. Shulzhenko, B. A. Akbalaeva, T. A. Batyraliev, O. V. Gurovich, R. K. Kalmatov, S. M. Mamatova, N. T. Jainakbayev, A. O. Seidalin, et al.

    Aim To monitor the dynamics of biomarkers during chemotherapy, targeted chemotherapy and targeted monotherapy in patients with HER2-positive breast cancer (BC); to analyze the emergence timing of these changes; to compare early biochemical and echocardiographic criteria; and to determine the best time for assessing latent subclinical cardiac dysfunction. Material and methods Patients with BC (229 women aged 57±11 years) treated sequentially with anthracyclines, a combination of docetaxel and trastuzumab, and trastuzumab monotherapy were examined during three blocks of BC therapy until the development of clinical cardiotoxicity. Time-related changes in high-sensitivity cardiac troponin I, N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular (LV) global longitudinal strain (GLS) and LV ejection fraction (EF) (up to 12 speckle-tracking echocardiograms/up to 12 laboratory tests) were analyzed. Clinical cardiotoxicity was defined as a symptomatic decrease in LV EF ≥10% from the baseline value of 54% or more. Results Clinically significant cardiotoxicity developed in 6.3-10.9% of cases depending on the treatment option for BC. Early manifestations of cardiotoxicity were detected already at 3 weeks after the start of the first course of chemotherapy. For the BC treatment with anthracyclines and targeted chemotherapy with docetaxel and trastuzumab, the markers of clinical cardiotoxicity were high-sensitivity cardiac troponin I, NT-proBNP and GLS LV. For the trastuzumab monotherapy, only GLS LV had a prognostic value. No statistically significant changes in the concentrations of high-sensitivity troponin I and NT-proBNP were found. Conclusion For timely detection of clinical cardiotoxicity, laboratory tests (high-sensitivity troponin I, NT-proBNP) and echocardiography (GLS LV) are recommended to be performed every 3 weeks before the next course of BC therapy. While doing so, their sensitivity will depend on the treatment option for BC.


  • Open Access

    FUNCTIONAL STATE OF THE CARDIOVASCULAR SYSTEM OF ADOLESCENT WATER POLO PLAYERS BEFORE AND AFTER EXERCISE USING A HARDWARE AND SOFTWARE COMPLEX «HEALTH-EXPRESS»

    by С. Э. Музрапова, М. Р. Камалиева, Р. Н. Сапаргалиев, Г. А. Нарбекова, M. Kamaliyeva, R. Sapargaliyev, Central Swimming Pool

    Water polo is a challenging aquatic sport. It requires versatile physical fitness. Intensive sports training induces specific changes in the cardiovascular system, as designated in sports medicine by the term "athletic heart." In Kazakhstan, this sport is one of the promising areas. The purpose of the study. To examine the state of the cardiovascular system in water sports athletes, including during physical activity, using innovative technologies (HSC «Health-Express»). Methods and Materials. This retrospective study involved 102 water polo athletes. Of these, 86 people met the inclusion criteria. The sample was formed based on selection, taking into account physical parameters, level of physical fitness, and the absence of contraindications to participation in the study. Results. After training, female athletes exhibited higher overall heart rate variability (MxDMn, SDNN, CV, Mo) and lower regulatory system stress indicators (Amo%, SI), indicating a less stressful recovery profile compared to male athletes. Conclusions. The study has shown that acute physical activity causes a decrease in parasympathetic activity and an increase in sympathetic activity, which is manifested in changes in key indicators of heart rate variability.

  • Open Access

    Speckle-Tracking Echocardiography in Assessment of Breast Cancer Therapy-Related Subclinical Cardiac Dysfunction

    by B. A. Akbalaeva, L. V. Shulzhenko, I. V. Pershukov, N. Raiimbek Uulu, T. A. Batyraliev, O. V. Gurovich, V. V. Vinogradskaia, N. T. Jainakbayev, A. O. Seidalin, M. R. Kamaliyeva

    Background: Cancer therapy-related cardiac dysfunction (CTRCD) is a new term that encompasses a wide range of potential manifestations and is etiologically associated with a wide variety of cancer treatments. Detection of early subclinical cardiac dysfunction is of great clinical importance.Objective: To assess subclinical CTRCD in women with HER2-positive locally advanced or metastatic breast cancer undergoing a course of anthracyclines (doxorubicin), docetaxel, and trastuzumab. We prospectively enrolled women aged 18-75 years with an established diagnosis of HER2-positive locally advanced or metastatic breast cancer across 3 centers.Material and methods: We monitored 122 women with HER2-positive locally advanced or metastatic breast cancer undergoing a course of anthracyclines (doxorubicin), docetaxel, and trastuzumab using speckle-tracking echocardiography. Based on the treatment protocol, we formed 3 comparison blocks: block 1 (chemotherapy: doxorubicin+cyclophosphamide); block 2 (chemotherapy+targeted therapy: docetaxel+trastuzumab), and block 3 (targeted therapy: trastuzumab).Results: The rate of subclinical CTRCD detection was high and exceeded 20%-30% in all comparison blocks after the 3rd course of chemotherapy, chemotherapy+targeted therapy, and targeted therapy. The rate of subclinical CTRCD increased significantly from the 1st to the 2nd, from the 2nd to the 3rd, from the 3rd to the 4th therapy courses in each block. Comparisons between the blocks were significant only after the 4th course of chemotherapy and the 4th course of targeted therapy (Yates-corrected chi-square, P=.0394); all the other comparisons between the blocks were not significant in terms of subclinical CTRCD rate.Discussion: Given the growing number of patients with breast cancer, such frequent monitoring of the cardiac function is likely to improve the quality of cancer treatment and might have a positive impact on the overall survival of patients with breast cancer. Conclusions: Criteria for frequency of echocardiographic monitoring of cardiac dysfunction in patients with malignant tumors, especially with HER2-positive breast cancer, should be revised.